Literature DB >> 21275952

Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate.

Emmanuel Bachy, Janine Bernaud, Pascal Roy, Dominique Rigal, Franck E Nicolini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21275952     DOI： 10.1111/j.1365-2141.2010.08453.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

Review 1.  Immunology and immunotherapy of chronic myeloid leukemia.

Authors:  Mette Ilander; Can Hekim; Satu Mustjoki
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

2.  Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients.

Authors:  Asmaa M Zahran; Hosny Badrawy; Abeer Ibrahim
Journal:  Int J Clin Oncol       Date:  2013-09-26       Impact factor: 3.402

Review 3.  Myeloid derived suppressor cells in chronic myeloid leukemia.

Authors:  Cesarina Giallongo; Nunziatina Parrinello; Maria Violetta Brundo; Salvatore Antonino Raccuia; Michelino Di Rosa; Piera La Cava; Daniele Tibullo
Journal:  Front Oncol       Date:  2015-05-15       Impact factor: 6.244

Review 4.  Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies.

Authors:  Giovanni D'Arena; Candida Vitale; Marta Coscia; Agostino Festa; Nicola Matteo Dario Di Minno; Vincenzo De Feo; Michele Caraglia; Gioacchino Calapai; Luca Laurenti; Pellegrino Musto; Giovanni Di Minno; Daniela Fenoglio
Journal:  J Immunol Res       Date:  2017-12-21       Impact factor: 4.818

Review 5.  Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.

Authors:  Amy Hughes; Agnes S M Yong
Journal:  Front Immunol       Date:  2017-04-24       Impact factor: 7.561

Review 6.  Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.

Authors:  Ruth Stuckey; Juan Francisco López-Rodríguez; Santiago Sánchez-Sosa; Adrián Segura-Díaz; Nuria Sánchez-Farías; Cristina Bilbao-Sieyro; María Teresa Gómez-Casares
Journal:  World J Clin Oncol       Date:  2020-12-24

Review 7.  Discontinuation of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: a Review of the Biological Factors Associated with Treatment-Free Remission.

Authors:  Ruth Stuckey; Juan Francisco López Rodríguez; María Teresa Gómez-Casares
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

8.  Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients.

Authors:  Cesarina Giallongo; Nunziatina Parrinello; Daniele Tibullo; Piera La Cava; Alessandra Romano; Annalisa Chiarenza; Ignazio Barbagallo; Giuseppe A Palumbo; Fabio Stagno; Paolo Vigneri; Francesco Di Raimondo
Journal:  PLoS One       Date:  2014-07-11       Impact factor: 3.240

9.  Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

Authors:  Cesarina Giallongo; Nunziatina L Parrinello; Piera La Cava; Giuseppina Camiolo; Alessandra Romano; Marina Scalia; Fabio Stagno; Giuseppe A Palumbo; Roberto Avola; Giovanni Li Volti; Daniele Tibullo; Francesco Di Raimondo
Journal:  J Cell Mol Med       Date:  2017-12-08       Impact factor: 5.310

Review 10.  Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.

Authors:  Fabien Muselli; Jean-François Peyron; Didier Mary
Journal:  Int J Mol Sci       Date:  2019-11-10       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.